Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 47 of 114

  1. Garetosmab

    Regeneron UK Limited

    Fibrodysplasia Ossificans Progressiva

    phase 3 small molecule active

    1 trial

  2. Gefarnate

    The First People's Hospital of Lianyungang

    Coronary Artery Disease

    phase 3 small molecule active

    1 trial

  3. Gefitinib

    AstraZeneca

    Non-Small-Cell Lung Carcinoma

    phase 3 small molecule completed

    1 trial

  4. Gefitinib

    AstraZeneca

    NSCLC

    phase 3 small molecule completed

    1 trial

  5. Gefitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  7. Gemcitabine

    AstraZeneca

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  8. Gemcitabine,Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  9. General anesthesia and opioids

    Elan Pharma International

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  10. Generic Budesonide/Formoterol Fumarate Dihydrate

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule completed

    1 trial

  11. Generic Estradiol Vaginal Cream USP, 0.01%

    Teva Pharma GmbH

    Atrophic Vaginitis

    phase 3 small molecule completed

    1 trial

  12. Generic Ivermectin Lotion 0.5%

    Teva Pharma GmbH

    Head Lice

    phase 3 small molecule completed

    1 trial

  13. Genotype-guided dosingTaiwan algorithm for warfarin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stroke

    phase 3 gene therapy completed

    1 trial

  14. Gepotidacin

    GlaxoSmithKline

    Urinary Tract Infections

    phase 3 small molecule completed

    1 trial

  15. Gilteritinib

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  16. Ginkgo Diterpene Lactone Meglumine Injection

    Universal Integrated

    Ischemic Stroke

    phase 3 small molecule active

    1 trial

  17. Ginkgo diterpene lactone meglumine injection

    Universal Integrated

    Ischemic Stroke, Acute

    phase 3 small molecule active

    1 trial

  18. Givosiran

    Alnylam Netherlands B.V.

    Acute Hepatic Porphyria

    phase 3 small molecule completed

    1 trial

  19. Glargine

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  20. Glatiramer Acetate

    Teva Pharma GmbH

    Optic Neuritis

    phase 3 small molecule completed

    1 trial

  21. Glatiramer Acetate (DB)

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  22. Glatiramer Acetate (GA) 40 mg

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  23. Glatiramer Acetate 20 mg/0.5 mL

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  24. Glatiramer acetate (GA)

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  25. Glecaprevir/Pibrentasvir

    AbbVie

    Hepatitis C Virus (HCV)

    phase 3 small molecule completed

    2 trials

  26. Glepaglutide 20.0 mg/mL

    Zealand Pharma A/S

    Short bowel syndrome

    phase 3 small molecule active

    1 trial

  27. Glepaglutide 20.0 mg/mL

    Zealand Pharma A/S

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial

  28. Glepaglutide 20.0 mg/mL, Glepaglutide Placebo

    Zealand Pharma A/S

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial

  29. Glimepiride

    Janssen Cilag International NV

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  30. Glipizide

    GlaxoSmithKline

    Atherosclerosis

    phase 3 small molecule completed

    1 trial

  31. Glucagon

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 3 small molecule completed

    1 trial

  32. Glucose 5% 50 ml

    Disc Medicine

    Apnea of prematurity

    phase 3 small molecule active

    1 trial

  33. Glycerin Suppository

    United Therapeutics Europe Ltd

    Encopresis

    phase 3 small molecule completed

    1 trial

  34. Glycopyrronium bromide

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    1 trial

  35. Golimumab 1 mg per kg

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 3 small molecule terminated

    1 trial

  36. Gonal-F

    The First People's Hospital of Lianyungang

    Anovulation

    phase 3 mab completed

    1 trial

  37. Grafalon 20 mg/ml concentrato per soluzione per infusione

    The George Institute

    To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.

    phase 3 small molecule active

    1 trial

  38. Granules for oral suspension, N-Acetyl-L-Leucine

    Intrabio Ireland Limited

    Niemann-Pick disease type C

    phase 3 small molecule active

    1 trial

  39. Granulocyte Colony-Stimulating Factor(G-CSF)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Myelodysplastic Syndrome

    phase 3 small molecule active

    2 trials

  40. Gum chewing

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Recovery of Bowel Function, Due to Gum Chewing

    phase 3 other active

    1 trial

  41. Guselkumab Dose 1

    Janssen Cilag International NV

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  42. Gynaecological follow-up

    GlaxoSmithKline

    Infections, Papillomavirus

    phase 3 other completed

    1 trial

  43. H. pylori vaccine

    Jiangsu Province Centers for Disease Control and Prevention

    H. Pylori Infection

    phase 3 mab completed

    1 trial

  44. H. pylori vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    H. Pylori Infection

    phase 3 mab completed

    1 trial

  45. H.22.03.01.09.A2

    United Therapeutics Europe Ltd

    Mortality Through Six Months of Age

    phase 3 other completed

    1 trial

  46. H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  47. H8H-MC-LAHV

    Eli Lilly Co.

    Migraine

    phase 3 small molecule active

    1 trial

  48. HBS-101-CL-312

    Harmony Biosciences Holdings

    Prader-Willi syndrome

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.